Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 275 No 7366 p308
10 September 2005

This article
Reprint   Photocopy

PDF 100K, Acrobat Reader

Letters

· Homoeopathy (5)
· Pharmacy practice
· Reciprocity
· NICE
· Retention fees
· Sexual health
· Media representation (3)
· Emergency supplies
· The Society


Letters to the Editor

Reciprocity

From the Society’s perspective

From Mr G. S. Phillips, MRPharmS

As the recently appointed chairman of the Royal Pharmaceutical Society’s Education Committee, I would like to take the opportunity to respond to the concerns of Ian Dean (PJ, 13 August, p194) and other colleagues.

When the Royal Pharmaceutical Society’s Council took its decision in 2003 to end reciprocal agreements with Australia and New Zealand it did so knowing the decision would be controversial. As Mr Dean points out, the Society thought a continuance of the existing agreements could be “construed as being discriminatory and risk legal challenge”. A key part of our thinking was the knowledge that new legislation stemming from the 1999 Health Act would not allow for reciprocal arrangements (not just for pharmacists but other professions too). Clearly the Society has no choice but to take this into account. This being the case I must correct one assertion made by Mr Dean: that the Society is out of step with other health care regulators in ending historical agreements. The reverse is true and the General Medical Council and General Dental Council have done the same thing recently for the same reasons.

David Newgreen (PJ, 27 August, p252) is right that EEA nationals can register in the UK but, unlike reciprocal agreements, that is a matter of EU law and we, like the competent authorities in all member states, are bound by it.

Furthermore it is not accurate to say applicants are accepted as a formality: every application is scrutinised fully by expert staff to ensure education and training is appropriate and in accordance with clearly defined EU requirements.

I accept Mr Newgreen’s points about standards of pharmacy education in Australia and New Zealand, which we know to be high and, for this reason, staff in the Society’s Education and Registration Directorate are actively exploring alternative mechanisms for recognising the competence of overseas pharmacists where there is a sound professional case for doing so. However, in a modern, regulatory environment, mechanisms must be transparent and no matter how seductive, not based on assertions such as “Britons and Australians are the most compatible of people, blending seamlessly and unnoticeably into each other’s communities” (Ian Dean, PJ, 13 August, p194).

There is a clear difference between pharmacy graduates in the UK and those from Australia and New Zealand in that we now require registrants to be educated to master’s level, whereas education in Australia and New Zealand remains at bachelor’s level. This is not to say that the education in Australia and New Zealand is inadequate, but it is different and we do have to acknowledge this.

It would not be fair or equitable to let applicants enter the Register in the knowledge that they have received different education to their UK equivalents, no matter how good it may be. We have to be sure that at the point of first registration in the UK all overseas pharmacists (not covered by EU legislation) have met the same criteria.

I would like to assure colleagues that there really is no hidden agenda in the action that the Society has taken — as a working community pharmacist I am all too acutely aware of the shortages within the profession.

The Society is continuing to work with pharmacy regulators overseas and is seeking to develop properly evaluated processes to assist the exchange of pharmacists between the UK and other jurisdictions. This process has already begun and I am aware that the President is taking a personal interest in this and in maintaining the best possible relations with our pharmaceutical cousins in Australia and New Zealand. Society staff will be meeting with colleagues overseas in the next few months to explore mutually acceptable ways forward.

Graham Phillips
Member of Council,
Chair of the Royal Pharmaceutical Society’s Education Committee

Send your letter to The Editor

Previous Topic (Pharmacy practice)
Next Topic (NICE)

Back to Top


©The Pharmaceutical Journal